Nivalis Therapeutics, Inc.
Nivalis Therapeutics, is a clinical stage pharmaceutical company that focuses on the discovery, development, and commercialization of drug candidates for people with cystic fibrosis (CF). CF is a life-shortening genetic disease. Our lead candidate is cavosonstat, a pill that is in two Phase II clinical trials intended to address a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The Company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.